Why the study?
Unfractionated heparin use is limited to patients at high risk of bleeding and thrombosis, rendering management challenging with unresolved questions despite decades of use.
This narrative review highlights critical unresolved issues in the management of therapeutic-intensity unfractionated heparin, calling for improved understanding of anti-Xa assays and revalidation of therapeutic ranges and dose adjustment nomograms.
No takes yet. Share an insight, caveat, or question.
Limitations in UFH monitoring warrant clinical caution; leaves open revalidation of ranges and nomograms in prospective studies.
Gouin‐Thibault et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: